| 臺大學術典藏 |
2022-03-10T02:31:38Z |
Safety and efficacy of pegylated liposomal doxorubicinbased adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer
|
Lien M.-Y.; Liu L.-C.; Wang H.-C.; Yeh M.-H.; Chen C.-J.; Yeh S.-P.; Bai L.-Y.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-C.; Li L.-Y.; PO-HAN LIN; Chiu C.-F. |
| 臺大學術典藏 |
2022-03-10T02:31:36Z |
A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice
|
PO-HAN LIN; Li H.-Y.; Fan S.-C.; Yuan T.-H.; Chen M.; Hsu Y.-H.; Yang Y.-H.; Li L.-Y.; Yeh S.-P.; Bai L.-Y.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-C.; Lin C.-H.; Lien M.-Y.; Chen T.-T.; Ni Y.-H.; Chiu C.-F. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients�� experience within a population-based study
|
Chiu T.-J.; Su Y.-Y.; SHIH-HUNG YANG; Li C.-P.; Bai L.-Y.; Chiang N.-J.; Chuang S.-C.; Shan Y.-S.; Chan D.-C.; Chen L.-T.; Yen C.-J.; Peng C.-M.; Chen Y.-Y.; Chen J.-S.; Chou W.-C. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
|
SHIH-HUNG YANG; Lu L.-C.; Kao H.-F.; Chen B.-B.; Kuo T.-C.; Kuo S.-H.; Tien Y.-W.; Bai L.-Y.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG; Jeng Y.-M.; Hsu C. |
| 臺大學術典藏 |
2022-02-14T07:10:49Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; Cheng A.-L.; YUNG-MING JENG; Hsu C. |
| 臺大學術典藏 |
2022-02-14T05:27:14Z |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu H.-M.; Tsai H.-J.; Ku H.-Y.; Lo S.-S.; Shan Y.-S.; Chang H.-C.; Chao Y.; Chen J.-S.; Chen S.-C.; Chiang C.-J.; Li A.F.-Y.; HSIU-PO WANG; Wang T.-E.; Bai L.-Y.; Wu M.-S.; Chen L.-T.; Liu T.-W.; Yang Y.-H. |
| 臺大學術典藏 |
2022-02-08T06:27:19Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Hsu C.-L.; DA-LIANG OU; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; Cheng A.-L.; Jeng Y.-M.; Hsu C. |
| 臺大學術典藏 |
2022-02-07T07:49:00Z |
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
|
Yang S.-H.; Lu L.-C.; Kao H.-F.; Chen B.-B.; Kuo T.-C.; SUNG-HSIN KUO; Tien Y.-W.; Bai L.-Y.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2022-01-25T07:24:16Z |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu H.-M.; Tsai H.-J.; Ku H.-Y.; Lo S.-S.; Shan Y.-S.; Chang H.-C.; Chao Y.; Chen J.-S.; Chen S.-C.; Chiang C.-J.; Li A.F.-Y.; Wang H.-P.; Wang T.-E.; Bai L.-Y.; MING-SHIANG WU; Chen L.-T.; Liu T.-W.; Yang Y.-H. |
| 臺大學術典藏 |
2022-01-05T03:36:40Z |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
|
Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2022-01-05T03:36:40Z |
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
|
Yang S.-H.; Lu L.-C.; Kao H.-F.; Chen B.-B.; Kuo T.-C.; Kuo S.-H.; Tien Y.-W.; Bai L.-Y.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2022-01-05T03:36:39Z |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. |
| 國立成功大學 |
2022 |
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
|
Chiang, N.-J.;Tan, K.T.;Bai, L.-Y.;Hsiao, C.-F.;Huang, C.-Y.;Hung, Y.-P.;Huang, C.-J.;Chen, S.-C.;Shan, Y.-S.;Chao, Y.;Huang, Y.-H.;Lee, I.-C.;Lee, P.-C.;Su, Y.-Y.;Chen, S.-J.;Yeh, C.-N.;Chen, L.-T.;Chen, M.-H. |
| 國立成功大學 |
2022 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chiu, T.-J.;Yang, S.-H.;Chiu, S.-C.;Hsueh, S.-W.;Chiang, N.-J.;Li, C.-P.;Bai, L.-Y.;Cheng, F.-M.;Chuang, S.-C.;Shan, Y.-S.;Chan, D.-C.;Chen, L.-T.;Yen, C.-J.;Peng, C.-M.;Su, Y.-Y.;Chen, Y.-Y.;Chen, J.-S.;Chou, W.-C. |
| 國立成功大學 |
2022 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr
|
Kang, Y.-K.;Chen, L.-T.;Ryu, M.-H.;Oh, D.-Y.;Oh, S.C.;Chung, H.C.;Lee, K.-W.;Omori, T.;Shitara, K.;Sakuramoto, Sakuramoto S.;Chung, I.-J.;Yamaguchi, K.;Kato, Kato K.;Sym, Sym S.J.;Kadowaki, S.;Tsuji, K.;Chen, J.-S.;Bai, L.-Y.;Oh, S.-Y.;Choda, Y.;Yasui, H.;Takeuchi, K.;Hirashima, Y.;Hagihara, S.;Boku, N. |
| 國立成功大學 |
2022 |
A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study
|
Bai, L.-Y.;Li, C.-P.;Shan, Y.-S.;Chuang, S.-C.;Chen, J.-S.;Chiang, N.-J.;Chen, Y.-Y.;Tsou, H.-H.;Chuang, M.-H.;Chiu, Chiu C.-F.;Liu, T.-W.;Chen, L.-T. |
| 臺大學術典藏 |
2021-09-15T01:20:45Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
CHIA-LANG HSU; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; Cheng A.-L.; Jeng Y.-M.; Hsu C. |
| 臺大學術典藏 |
2021-09-01T01:54:02Z |
Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer
|
Kuo W.-H.; Lin P.-H.; Huang A.-C.; Chien Y.-H.; Liu T.-P.; Lu Y.-S.; Bai L.-Y.; Sargeant A.M.; Lin C.-H.; ANN-LII CHENG; Hsieh F.-J.; Hwu W.-L.; Chang K.-J. |
| 臺大學術典藏 |
2021-06-03T06:15:36Z |
A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice
|
PO-HAN LIN; Li H.-Y.; Fan S.-C.; Yuan T.-H.; Chen M.; Hsu Y.-H.; Yang Y.-H.; Li L.-Y.; Yeh S.-P.; Bai L.-Y.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-C.; Lin C.-H.; Lien M.-Y.; Chen T.-T.; Ni Y.-H.; Chiu C.-F. |
| 臺大學術典藏 |
2021-01-28T01:06:35Z |
A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer
|
Chao Y.;Hsieh J.-S.;Yeh H.-T.;Su Y.-C.;Wu C.-C.;Chen J.-S.;Tai C.-J.;Bai L.-Y.;Kun-Huei Yeh;Su W.-C.;Li C.-P.; Chao Y.; Hsieh J.-S.; Yeh H.-T.; Su Y.-C.; Wu C.-C.; Chen J.-S.; Tai C.-J.; Bai L.-Y.; KUN-HUEI YEH; Su W.-C.; Li C.-P. |
| 臺大學術典藏 |
2021-01-28T01:06:21Z |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang Y.-K.;Boku N.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Chen L.-T.; Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-28T01:06:17Z |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh T.; Kang Y.-K.; Chao Y.; Ryu M.-H.; Kato K.; Cheol Chung H.; Chen J.-S.; Muro K.; Ki Kang W.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Tanimoto M.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2021-01-28T01:06:16Z |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen L.-T.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Sameshima H.;Kang Y.-K.;Boku N.; Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. |
| 國立成功大學 |
2021 |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu, Hu H.-M.;Tsai, H.-J.;Ku, H.-Y.;Lo, S.-S.;Shan, Y.-S.;Chang, H.-C.;Chao, Y.;Chen, J.-S.;Chen, S.-C.;Chiang, Chiang C.-J.;Li, A.F.-Y.;Wang, H.-P.;Wang, T.-E.;Bai, L.-Y.;Wu, M.-S.;Chen, L.-T.;Liu, T.-W.;Yang, Yang Y.-H. |
